Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. News
  7. Summary
    NOTV   US45783Q1004


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inotiv Set to Join Russell 3000« Index and Russell 2000« Index

06/07/2021 | 04:15pm EDT

WEST LAFAYETTE, Ind., June 07, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company is set to join the broad-market Russell 3000® Index and Russell 2000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. markets open on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer, said, “Inotiv’s inclusion on the preliminary list of additions to the Russell 3000® Index is a positive milestone, reflecting our success building a comprehensive suite of research solutions across the drug discovery and pre-clinical development continuum. We believe that inclusion in the Russell indices may generate greater institutional investor awareness of our growth opportunity.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About the Company
Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company ContactInvestor Relations
Inotiv, Inc.The Equity Group Inc.
Beth A. Taylor, Chief Financial OfficerKalle Ahl, CFA
(765) 497-8381(212) 836-9614
 Devin Sullivan
 (212) 836-9608

Primary Logo

ę GlobeNewswire 2021
All news about INOTIV, INC.
03:53pSECTOR UPDATE : Health Care Stocks Add Support As Monday Trading Turns Increasin..
02:03pINOTIV : Acquires Gateway Pharmacology Labs, Adding to Its Drug Metabolism, Phar..
12:15pINOTIV : Announces Acquisition of Gateway Pharmacology Laboratories
07/30FRONTAGE : Concludes Purchase of US-Based Quintara Discovery
07/22INOTIV : to Report Third Quarter Fiscal 2021 Financial Results and Host Conferen..
07/21Certain Common Shares of Inotiv, Inc. are subject to a Lock-Up Agreement Endi..
07/21Certain Options of Inotiv, Inc. are subject to a Lock-Up Agreement Ending on ..
07/15SECTOR UPDATE : Health Care Stocks Lower Just Ahead of Closing Bell
07/15SECTOR UPDATE : Health Care Stocks Lacking Much Traction
07/15INOTIV : Buys Laboratories Assets in Tennessee for About $1.3 Million
More news
Financials (USD)
Sales 2021 80,2 M - -
Net income 2021 -2,26 M - -
Net Debt 2021 - - -
P/E ratio 2021 -145x
Yield 2021 -
Capitalization 413 M 413 M -
Capi. / Sales 2021 5,15x
Capi. / Sales 2022 3,28x
Nbr of Employees 409
Free-Float 62,3%
Duration : Period :
Inotiv, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOTIV, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 26,12 $
Average target price 36,00 $
Spread / Average Target 37,8%
EPS Revisions
Managers and Directors
Robert Leasure President, Chief Executive Officer & Director
Beth A. Taylor Chief Financial Officer, Secretary & VP-Finance
Gregory C. Davis Chairman
John Gregory Beattie Chief Operating Officer
Richard Allen Johnson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INOTIV, INC.0.00%413
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
CELLTRION, INC.-26.60%30 059
SEAGEN INC.-12.42%27 907